Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix vs Leuprolide in Prostate Cancer (REPLACE-CV)
NCT05605964Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of relugolix in prostate cancer (PCa), sponsored by Sumitomo Pharma America. Started Jan 2023; status: completed.
02
Drugs
relugolix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05605964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605964.